GUMULEC, Jaromír, Natalia Vladimirovna CERNEI, Ondřej ZÍTKA, Michal MASAŘÍK, Petr BABULA, Vojtěch ADAM and René KIZEK. Zinc, Metallothionein and Prostate Tumour Cells - Is There Any Relation? In 10th International Nutrition & Diagnostics Conference. 2010. ISBN 978-80-7395-257-0.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Zinc, Metallothionein and Prostate Tumour Cells - Is There Any Relation?
Name in Czech Zinek, metalothionein a buňky karcinomu prostaty - jaká je spojitost?
Authors GUMULEC, Jaromír, Natalia Vladimirovna CERNEI, Ondřej ZÍTKA, Michal MASAŘÍK, Petr BABULA, Vojtěch ADAM and René KIZEK.
Edition 10th International Nutrition & Diagnostics Conference, 2010.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW International Nutrition & Diagnostics Conference
Organization unit Faculty of Medicine
ISBN 978-80-7395-257-0
Keywords (in Czech) zinek;karcinom prostaty;prostata;nádorový marker;metalothionein;PC-3
Keywords in English zinc;prostate cancer;prostate;tumor marker;metallothionein;PC-3
Tags International impact
Changed by Changed by: doc. MUDr. Jaromír Gumulec, Ph.D., učo 185198. Changed: 29/11/2010 00:34.
Abstract
Prostate cells are unique in zinc metabolism, because they have the ability to accumulate high levels of these ions. In contrast, prostate cancer cells lack this ability. Metallothioneins (MT) are proteins rich in cysteine. They can bind metals including zinc. Recent studies indicate to elevated serum levels of MTin patients suffering from prostate cancer. Moreover, elevated serum levels of MT are highly specific for prostate cancer and can be potentially used as a new marker of this disease. This could be very desirable because of inaccuracies of current prostatic specific antigen (PSA) screening. The aims of this study is (1) to determine MT levels in patient's serum and cell lines PC-3 and 22RVL and compare to PSA levels, (2) to determine expression of zinc transporters in cell lines and find relations between MT and intracellular zinc levels, (3) to describe potential effects of MT and/or zinc on prostate cancer pathogenesis.
Links
GP301/09/P436, research and development projectName: Analýza metalothioneinu u karcinomu prostaty na úrovni DNA, RNA a proteinu.
Investor: Czech Science Foundation
KAN208130801, research and development projectName: Nové konstrukce a využití nanobiosenzorů a nanosenzorů v medicíně (NANOSEMED)
NS10200, research and development projectName: Nádorové markery, jejich stanovení a korelace s karcinomem prostaty
Investor: Ministry of Health of the CR
PrintDisplayed: 7/5/2024 13:31